This compound has been proved in several cancer cell lines, and there are studies that demonstrated that it is an inhibitor of DNMT1 with an IC50 of 2 μM for A549 cell line (human lung cancer cell line harboring wild-type p53), an IC50 of 20 μM for U373MG cell line (human glioblastoma cell line harboring inactive mutant p53) [19], and an IC50 of 30 μM for Hut78 cell line (cutaneous T cell lymphoma) [20,21]. The gene discussed is TP53; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.